Results 71 to 80 of about 4,076 (204)

Levetiracetam Affects Differentially Presynaptic Proteins in Rat Cerebral Cortex

Frontiers in Cellular Neuroscience, 2017
Presynaptic proteins are potential therapeutic targets for epilepsy and other neurological diseases. We tested the hypothesis that chronic treatment with the SV2A ligand levetiracetam affects the expression of other presynaptic proteins.
Daniele Marcotulli, Giorgia Fattorini, Giorgia Fattorini, Luca Bragina, Luca Bragina, Jessica Perugini, Fiorenzo Conti, Fiorenzo Conti   +7 more
doaj   +1 more source

Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2

Nature Communications, 2023
Botulinum neurotoxin E (BoNT/E) is one of the major causes of human botulism and paradoxically also a promising therapeutic agent. Here we determined the co-crystal structures of the receptor-binding domain of BoNT/E (HCE) in complex with its neuronal ...
Zheng Liu, Pyung-Gang Lee, Nadja Krez, Kwok-ho Lam, Hao Liu, Adina Przykopanski, Peng Chen, Guorui Yao, Sicai Zhang, Jacqueline M. Tremblay, Kay Perry, Charles B. Shoemaker, Andreas Rummel, Min Dong, Rongsheng Jin   +14 more
doaj   +1 more source

Identification of pre-synaptic density networks using [11C]UCB-J PET imaging and ICA in mice

NeuroImage, 2022
Background: Synaptic vesicle glycoprotein 2A (SV2A) is a vesicle glycoprotein involved in neurotransmitter release. SV2A is located on the pre-synaptic terminals of neurons and visualized using the radioligand [11C]UCB-J and positron emission tomography (
Jordy Akkermans, Franziska Zajicek, Alan Miranda, Mohit H. Adhikari, Daniele Bertoglio   +4 more
doaj   +1 more source

A posttranslational proteomic survey of a single anatomically preserved human 20‐week postconception brain

Journal of Anatomy, EarlyView.
A well‐preserved 20 post‐conception week human brain was obtained and finely dissected into 18 anatomically distinct regions, including the pia mater. Each region underwent in‐depth proteomic analysis, encompassing both total protein content and post‐translational modifications.
S. Bandiera, H. Bogetofte, P. Jensen, R. Hussain, S. A. Nischal, L. Rihova, G. J. Clowry, M. R. Larsen, Z. Molnár, B. C. Carlyle   +9 more
wiley   +1 more source

The MacBrain Resource Center (MBRC) rhesus macaque postnatal brain histology datasets: Enabling new discoveries through NHP tissue and digital data Repositories

Journal of Anatomy, EarlyView.
The MacBrain Resource Center (MBRC) postnatal rhesus macaque brain histology datasets are organized into Collections that promote cost‐effective de novo research. This article provides examples from Collections 5, 6, and 7 and describes the histo‐ and immunohistochemical (IHC) processing of materials for Collection 6.
Valeria Mendoza‐Silva, Lucy Greene, Emma Burke, Cristina Canales, Julia Chocarro, Jose L. Lanciego, Khuleshwari Kurrey, Phil Barello, Aya Nusir, Nadine Kabbani, Kathleen S. Rockland, Dibyadeep Datta, Jon I. Arellano, Amy F. T. Arnsten, Yury M. Morozov, Bashir Ahmed, Zoltán Molnár, Caroline J. Zeiss, Pasko Rakic, Alvaro Duque   +19 more
wiley   +1 more source

Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A) [PDF]

Proceedings of the National Academy of Sciences, 1999
Synaptic vesicle protein 2 (SV2) is a membrane glycoprotein common to all synaptic and endocrine vesicles. Unlike many proteins involved in synaptic exocytosis, SV2 has no homolog in yeast, indicating that it performs a function unique to secretion in higher eukaryotes. Although the structure and protein interactions of SV2 suggest
K M, Crowder, J M, Gunther, T A, Jones, B D, Hale, H Z, Zhang, M R, Peterson, R H, Scheller, C, Chavkin, S M, Bajjalieh   +8 more
openaire   +2 more sources

SV2B and SV2C are not upregulated in the absence of SV2A in the hippocampus.

, 2016
A: SV2B mRNA expression in the hippocampus of WT and Grik4:SV2A-cKO mice, measured by quantitative real-time PCR. The SV2A mRNA levels were normalized using the GAPDH mRNA levels.
Guillaume Becker (1811236), Sabine Wislet (3353177), Catherine Menten-Dedoyart (268642), Priscilla Van den Ackerveken (3353168), Odile Bartholome (3353174), Virginie Neirinckx (129045), Judit Sánchez Gil (3353171), Alain Plenevaux (1638856), Maria Elisa Serrano Navacerrada (3353165), Bernard Rogister (4738)   +9 more
core   +1 more source

Neurotransmitter‐Defined Degeneration Patterns in Sporadic and C9orf72‐Associated Amyotrophic Lateral Sclerosis: Predilection to GABAergic, Serotonergic, Opioid, Glutamatergic, Endocannabinoid, and Microglial Systems—Implications for Therapy Development

Annals of Neurology, Volume 100, Issue 5, Page 948-961, November 2026.
Objective Amyotrophic lateral sclerosis (ALS) has a markedly distinctive clinical and neuroradiological signature, with the preferential involvement of specific brain networks and the apparent sparing of others. The molecular underpinnings of the strikingly selective anatomical vulnerability have not been fully elucidated to date despite the potential ...
Marlene Tahedl, We Fong Siah, Jasmin Lope, Jennifer C. Hengeveld, Mark A. Doherty, Russell L. McLaughlin, Orla Hardiman, Ee Ling Tan, Alison Toomey, Jana Kleinerova, Peter Bede   +10 more
wiley   +1 more source

Glycosylated SV2A and SV2B Mediate the Entry of Botulinum Neurotoxin E into Neurons [PDF]

Molecular Biology of the Cell, 2008
Botulinum neurotoxin E (BoNT/E) can cause paralysis in humans and animals by blocking neurotransmitter release from presynaptic nerve terminals. How this toxin targets and enters neurons is not known. Here we identified two isoforms of the synaptic vesicle protein SV2, SV2A and SV2B, as the protein receptors for BoNT/E.
Min, Dong, Huisheng, Liu, William H, Tepp, Eric A, Johnson, Roger, Janz, Edwin R, Chapman   +5 more
openaire   +2 more sources

Beneficial Role of Natural Polyphenols Against Epilepsy: Greasing the Wheels of Pharmacotherapy Research for Epilepsy

Food Frontiers, Volume 7, Issue 6, November 2026.
ABSTRACT Epilepsy is the most disabling neurological disease that affects all economic classes, age groups, regions, and races. Although many antiseizure drugs are approved for epilepsy treatment, they fail to work in about 30%–40% of patients. Thus, there is a great need to identify better pharmacological agents to treat epilepsy.
Janakiraman Pillai Udaiyappan, Rengasamy Balakrishnan, Manivasagam Muthukumaran Tamilarasan, Subasri Pandian   +3 more
wiley   +1 more source